Table 2.
Patients’ characteristics (n = 56).
| Category | n (%) |
|---|---|
| Gender | |
| Women | 29 (51.8) |
| Age (years), median [range] | 49.6 [23–73] |
| Smoking status | |
| Current or former | 24 (42.9) |
| Non-smoker | 26 (46.4) |
| Not applicable | 5 (8.9) |
| Histology | |
| Adenocarcinoma | 56 (100) |
| Stage | |
| Locally advanced | 7 (12.5) |
| Metastatic | 49 (87.5) |
| Number of metastatic sites | |
| 1 | 17 (30.4) |
| ≥ 2 | 39 (69.6) |
| Brain Metastasis (BM) | 14 (25) |
| N. Prior treatment lines | n (%) |
| Average | 2.4 (1–8) |
| ≤ 2 lines of therapy | 33 (59) |
| > 2 lines of therapy | 23 (41) |
| Chemotherapy first | 31 (55.4) |
| ALK-TKI first | 25 (44.6) |
| TKI at the time of plasma collection | |
| Crizotinib | 17 (30.3) |
| Lorlatinib | 16 (28.6) |
| Ceritinib | 13 (23.2) |
| Alectinib | 3 (5.4) |
| Other | 7 (12.5) |